Andrzej Jakubowiak, MD, PhD
Enriched profileProfessor of Medicine, Director of the Myeloma Program · University of Chicago
Andrzej Jakubowiak is Professor of Medicine, Director of the Myeloma Program at University of Chicago. OpenAlex indexes 477 publications with 23,306 citations (h-index 68); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Andrzej Jakubowiak is Professor of Medicine, Director of the Myeloma Program at University of Chicago, Department of Medicine, Section of Hematology/Oncology. The public record shows 477 publications with 23,306 citations (h-index 68), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T cell therapy research. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 16 companies.
- Most recent indexed publication: 2026 · Science translational medicine
- Top research focus: Multiple Myeloma Research and Treatments
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 214.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
Sponsor: University of Chicago
Industry payments
Updated 27 Aug 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- Adaptive Biotechnologies CorporationProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
86%Thalidomide Analog78.7%Revlimid42%Lenalidomide31%Pomalyst27%Part D≥21 patientsBCL-2 Inhibitor7.3%Venclexta100%Part D<11 patientsDermatology
5.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor5.7%Acyclovir100%Part D<11 patientsBlood & clotting
4.3%Factor Xa inhibitor4.3%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
113 congress contributions (2006–2025) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
- B cell kinetics on next generation sequencing after CAR T-cell therapy in multiple myeloma
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
Science translational medicine
Clinical Trial2026 - Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Cancer immunology research
Clinical Trial2026 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.
Journal of clinical oncology
Article2025
Most-cited works
by citation count (OpenAlex)- 02Initial genome sequencing and analysis of multiple myeloma1,440 citations2011
- 03Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma1,325 citations2014
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/andrzej-jakubowiak-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/andrzej-jakubowiak-a018a96a
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/ajjakubowiak
Mentions by others
where others cite or feature them- Other
onclive.com/authors/andrzej-jakubowiak-md-phd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - X / Twitter
x.com/UCCancerCenter/status/1929204488692175235
- X / Twitter
x.com/UCCancerCenter/status/2034681581449650233
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- MD
Poznan University of Medical Sciences, Poland
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biologicalsciences.uchicago.edu ↗ - PhD
Poznan University of Medical Sciences, Poland
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biologicalsciences.uchicago.edu ↗ - Board Certified
Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uchicagomedicine.org ↗
Editorial & leadership roles
journal and society appointments- Lead investigator
multiple multi-site clinical trials in newly diagnosed, relapsed, and refractory multiple myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biologicalsciences.uchicago.edu ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nature.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biologicalsciences.uchicago.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biologicalsciences.uchicago.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biologicalsciences.uchicago.edu ↗
Secondary affiliations
appointments beyond the home institution- Duchossois Center for Advanced Medicine
UChicago Medicine (clinical practice location)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Everett Vokes, MD
University of Chicago
Ralph Weichselbaum, MD
University of Chicago
Mary Rinella, MD
University of Chicago
Hedy Kindler, MD
University of Chicago